BioScience Health Innovations annual total liabilities
2020
2021
2022
2022
2023
2024
2025
BioScience Health Innovations Total Liabilities Growth & History (BHIC)
BioScience Health Innovations's total liabilities was $229,851 for fiscal 2025.
View full BioScience Health Innovations company overviewBioScience Health Innovations annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $229,851 | $191,303 | +496.27% |
| 2024 | 2024-12-31 | $38,548 | −$61,600 | −61.51% |
| 2023 | 2023-12-31 | $100,148 | $51,357 | +105.26% |
| 2022 · Dec 31 | 2022-12-31 | $48,791 | — | — |
| 2022 · Aug 31 | 2022-08-31 | $1,860 | −$17,246 | −90.26% |
| 2021 | 2021-08-31 | $19,106 | $11,295 | +144.60% |
| 2020 | 2020-08-31 | $7,811 | — | — |
BioScience Health Innovations quarterly total liabilities
As of Aug 31, 2019
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q4.22
Q1.23
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $301,209 | −$36,423 | −10.79% |
| Q1 2026 | 2026-03-31 | $645,749 | $512,828 | +385.81% |
| Q4 2025 | 2025-12-31 | $229,851 | $191,303 | +496.27% |
| Q3 2025 | 2025-09-30 | $356,140 | $310,593 | +681.92% |
| Q2 2025 | 2025-06-30 | $337,632 | $313,123 | +1277.58% |
| Q1 2025 | 2025-03-31 | $132,921 | $92,982 | +232.81% |
| Q4 2024 | 2024-12-31 | $38,548 | −$61,600 | −61.51% |
| Q3 2024 | 2024-09-30 | $45,547 | −$40,852 | −47.28% |
| Q2 2024 | 2024-06-30 | $24,509 | −$92,710 | −79.09% |
| Q1 2024 | 2024-03-31 | $39,939 | −$76,427 | −65.68% |
| Q4 2023 | 2023-12-31 | $100,148 | $51,357 | +105.26% |
| Q3 2023 | 2023-09-30 | $86,399 | — | — |
| Q2 2023 | 2023-06-30 | $117,219 | — | — |
| Q1 2023 · Mar 31 | 2023-03-31 | $116,366 | — | — |
| Q1 2023 · Feb 28 | 2023-02-28 | $3,302 | −$12,213 | −78.72% |
| Q4 2022 · Dec 31 | 2022-12-31 | $48,791 | — | — |
| Q1 2023 · Nov 30 | 2022-11-30 | $2,867 | −$20,148 | −87.54% |
| Q4 2022 · Aug 31 | 2022-08-31 | $1,860 | −$17,246 | −90.26% |
| Q3 2022 | 2022-05-31 | $16,748 | $7,737 | +85.86% |
| Q2 2022 | 2022-02-28 | $15,515 | $7,704 | +98.63% |
| Q1 2022 | 2021-11-30 | $23,015 | $10,204 | +79.65% |
| Q4 2021 | 2021-08-31 | $19,106 | $11,295 | +144.60% |
| Q3 2021 | 2021-05-31 | $9,011 | $1,850 | +25.83% |
| Q2 2021 | 2021-02-28 | $7,811 | −$154 | −1.93% |
| Q1 2021 | 2020-11-30 | $12,811 | $6,696 | +109.50% |
| Q4 2020 | 2020-08-31 | $7,811 | $7,811 | — |
| Q3 2020 | 2020-05-31 | $7,161 | — | — |
| Q2 2020 | 2020-02-29 | $7,965 | — | — |
| Q1 2020 | 2019-11-30 | $6,115 | — | — |
| As of Aug 31, 2019 | 2019-08-31 | $0 | — | — |
BioScience Health Innovations total liabilities trends
Between the periods ended 2020-08-31 and 2025-12-31, BioScience Health Innovations's total liabilities increased from $7,811 to $229,851, a change of $222,040. The latest reported quarter, Q2 2026, shows $301,209.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioScience Health Innovations source filings ↗